Integra Lifesciences Holdings Corp (NASDAQ:IART) price on Friday, February 07, fall -3.07% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $25.22.
A look at the stock’s price movement, the close in the last trading session was $26.02, moving within a range at $25.18 and $26.275. The beta value (5-Year monthly) was 1.084. Turning to its 52-week performance, $45.42 and $16.81 were the 52-week high and 52-week low respectively. Overall, IART moved 13.86% over the past month.
Integra Lifesciences Holdings Corp’s market cap currently stands at around $1.95 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 445.15M for the company’s revenue for the quarter, with a low and high estimate of 442.2M and 447.84M respectively. The average forecast suggests up to a 12.12% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.61B, representing a 4.64% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IART is a 100% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 2 recommend IART as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IART’s current price about 1.25% and 5.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 53.82, while 7-day volatility ratio is 3.36% and 3.72% in the 30-day chart. Further, Integra Lifesciences Holdings Corp (IART) has a beta value of 1.22, and an average true range (ATR) of 0.88. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. Looking at the price targets, the low is 20.7% off current price level while to achieve the yearly target high, price needs to move 20.7%. Nonetheless, investors will most likely welcome a 20.7% jump to $20 which is the analysts’ median price.
If we refocus on Integra Lifesciences Holdings Corp (NASDAQ:IART), historical trading data shows that trading volumes averaged 0.49 over the past 10 days and 626.67K over the past 3 months. The company’s latest data on shares outstanding shows there are 77.13 million shares.
The 14.31% of Integra Lifesciences Holdings Corp’s shares are in the hands of company insiders while institutional holders own 92.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.37 million on 2025-01-15, giving us a short ratio of 6.18. The data shows that as of 2025-01-15 short interest in Integra Lifesciences Holdings Corp (IART) stood at 508.0 of shares outstanding, with shares short falling to 3.45 million registered in 2024-12-13. Current price change has pushed the stock 11.20% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IART stock continues to rise going into the next quarter.
